Navigation Links
Genetic testing not cost-effective in guiding initial dosing of common blood thinner
Date:1/19/2009

ty-adjusted life year gained.

In other analyses, where they took into consideration the limitations of the studies, researchers found that there is only a 10 percent chance that genotype-guided dosing is likely to be cost-effective.

Researchers also looked at the impact of other variables on the cost-effectiveness of genotype-guided dosing.

Eckman says results show that genotype-guided dosing might be worth the costs if it:

  • Is used for patients at high risk for hemorrhage
  • Prevents more than 32 percent of major bleeding events
  • Is available within 24 hours
  • Costs less than $200

"This could be accomplished if testing were done in-house, at lower cost and without delays," he says, noting that currently in most cases these tests need to be sent to outside laboratories which can lead to delays in starting treatment and increased cost. "Furthermore, future studies, such as the recently funded National Institutes of Health COAG trial, need to examine the impact of pharmacogenetic-guided dosing on bleeding risk and monitor outcomes long enough to determine the true duration of benefit."

Eckman also suggests that rather than excluding patients at higher risk for bleeding, studies should offer enrollment if it has already been determined that these patients require warfarin.

"Personalized, predictive medicine offers great promise, but we need to carefully examine the benefits and understand the cost-effectiveness of such strategies before we spend a lot of money on very expensive tests."


'/>"/>

Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati
Source:Eurekalert

Page: 1 2

Related biology news :

1. Rethinking the genetic theory of inheritance
2. Biologist enhances use of bioinformatic tools and achieves precision in genetic annotation
3. MUHC and McGill scientists explain genetic disease first discovered in Quebec 24 years ago
4. New drug holds out promise of normal diet for sufferers of devastating PKU genetic disease
5. Growth of new brain cells requires epigenetic switch
6. Studies examine genetic determinants of ADHD
7. Genetic mutation causes familial susceptibility for degenerative brain disease
8. New genetic markers for ulcerative colitis identified, researchers report in Nature Genetics
9. Genetic variation may lead to early cardiovascular disease
10. Scientists make strides toward defining genetic signature of Alzheimers disease
11. Safe new therapy for genetic heart disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2015)... 2015 SoundView Technology Group issues a new research ... ) Wocket smart wallet. SoundView was one of the selected user ... with the Wocket in multiple scenarios and outlets. ... other retailers, making both debit and credit card payments.  ... "If the company meets their plans in 2015, it would ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for ...
(Date:3/17/2015)... 2015 MedNet Solutions , a ... study management systems, is pleased to announce that ... Outsourcing in Clinical Trials Southeast conference – March ... excellent forum for MedNet to showcase iMedNet ... (SaaS) eClinical technology platform. We strongly ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... A team of scientists led by the Department of Energy,s ... is publishing this week the first genome sequence of an ... in a major gap among the vertebrates sequenced to date. ... far fewer other vertebrates," said co-author Richard Harland, UC Berkeley ...
... not just sap-sucking, plant-destroying enemies of agriculture. In fact, ... traits, according to a study that appears in the ... First, aphids are, so far, the only ... The aphid,s pigment-producing ability is unique to the animal ...
... A new study from the University of Rochester finds ... brain that gives it language capabilities above and beyond those ... regions of the brain, each designed to accomplish different primitive ... on the type of grammar used in forming a given ...
Cached Biology News:Scientists report first genome sequence of frog 2Scientists report first genome sequence of frog 3Scientists report first genome sequence of frog 4Aphids evolved special, surprising talents 2Sign language study shows multiple brain regions wired for language 2Sign language study shows multiple brain regions wired for language 3
(Date:4/16/2015)... DIEGO , April 16, 2015 Avelas ... dedicated to improving cancer surgeries, announced today that it ... fluorescent cancer illuminator, AVB-620, in women with primary, non-recurrent ... the company also welcomed the addition of Steven ... The open label, dose escalation study will ...
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
(Date:4/16/2015)... NJ (PRWEB) April 16, 2015 ... Dr. Joseph V. Gulfo to become the Executive ... Entrepreneurship. Simultaneously, FDU announced the kick-off of the ... program spearheaded by Dr. Gulfo, under the Rothman ... College of Business) and in collaboration with FDU’s ...
(Date:4/16/2015)... 2015 Dana-Farber Cancer Institute and ... Resolution Bioscience, Inc. today announced the successful completion ... blood-based, clinic ready, Next Generation Sequencing (NGS) assay ... is the first to demonstrate the successful sequencing ... in blinded plasma samples and highlights the ability ...
Breaking Biology Technology:Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3
... the American College of Cardiology 57th Annual ... Scientific ... VRML ), a molecular diagnostics company, presented data from a,study ... the diagnosis of peripheral artery disease,(PAD). The research suggests that such ...
... Expansion of Remergent Skincare Line, FREEPORT, N.Y., ... focused on the development and sale of skincare,products ... a $5,million investment round led by existing investor ... The new capital is being used to ...
... Sirion Therapeutics, Inc., a,privately held ophthalmic-focused ... from two Phase 3 clinical trials of,Durezol(TM) ... in,the treatment of postoperative ocular inflammation. The ... Korenfeld, MD during the American Society of,Cataract ...
Cached Biology Technology:Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease 2Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease 3Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium 2Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium 3
Mouse Ameloblastin Biotinylated Affinity Purified PAb ENTREZ GeneID: 11698...
Human SOST Affinity Purified Polyclonal Ab...
Homo sapiens CDC23 (cell division cycle 23, yeast, homolog),...
Human FADD Affinity Purified Polyclonal Ab...
Biology Products: